Literature DB >> 9879421

Effect of zinc sulfate on sensorineural olfactory disorder.

T Aiba1, M Sugiura, J Mori, K Matsumoto, K Tomiyama, F Okuda, Y Nakai.   

Abstract

We administered zinc sulfate to patients with sensorineural (post-viral, post-traumatic, or unknown aetiology) olfactory disorder and examined its effects. The patients were divided into three groups by method of treatment: zinc sulfate only, combination of zinc sulfate and the usual therapy, or the usual therapy. For disorders of post-viral and unknown aetiologies, there were no significant differences in improvement among the three groups. However, for post-traumatic olfactory disorder, the zinc sulfate groups had significantly higher improvement rates than did the group that received the usual therapy. The difference between post-traumatic and post-viral olfactory disorders in the effect of zinc sulfate therapy appeared to depend on the pathology of the associated lesions. In cases of post-traumatic olfactory disorder, regenerative capacity is retained in the olfactory epithelium because the blast cells of olfactory receptor cells remain intact. However, for post-viral olfactory disorder, the lack of olfactory receptor cells and blast cells due to viral infection results in loss of regenerative capacity. We also determined pre-treatment serum zinc concentrations in those patients who planned to be treated with zinc sulfate. Pre-treatment serum zinc concentration was not significantly related to improvement rates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9879421     DOI: 10.1080/00016489850182936

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  9 in total

1.  Cranial nerve I: olfaction.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Psychiatry (Edgmont)       Date:  2009-07

2.  Steroid treatment of posttraumatic anosmia.

Authors:  Rong-San Jiang; Shang-Heng Wu; Kai-Li Liang; Jiun-Yih Shiao; Chung-Han Hsin; Mao-Chang Su
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-04-09       Impact factor: 2.503

Review 3.  Nanomedicine in otorhinolaryngology: what does the future hold?

Authors:  Carl M Philpott; Simon Gane; David McKiernan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-11-27       Impact factor: 2.503

4.  Treatment strategies for postviral olfactory dysfunction: A systematic review.

Authors:  Samuel N Helman; Jonah Adler; Aria Jafari; Sasha Bennett; Jackson R Vuncannon; Ashley C Cozart; Sarah K Wise; Merin E Kuruvilla; Joshua M Levy
Journal:  Allergy Asthma Proc       Date:  2022-03-01       Impact factor: 2.587

5.  Re-establishment of olfactory and taste functions.

Authors:  Antje Welge-Lüssen
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 6.  Treatment of post-viral olfactory dysfunction: an evidence-based review with recommendations.

Authors:  Nanki Hura; Deborah X Xie; Garret W Choby; Rodney J Schlosser; Cinthia P Orlov; Stella M Seal; Nicholas R Rowan
Journal:  Int Forum Allergy Rhinol       Date:  2020-06-25       Impact factor: 3.858

7.  Effects of Tokishakuyakusan on Regeneration of Murine Olfactory Neurons In Vivo and In Vitro.

Authors:  Takuya Noda; Hideaki Shiga; Kentaro Yamada; Masayuki Harita; Yukari Nakamura; Tomoko Ishikura; Masami Kumai; Zenji Kawakami; Atsushi Kaneko; Toshihisa Hatta; Hiromi Sakata-Haga; Hiroki Shimada; Takaki Miwa
Journal:  Chem Senses       Date:  2019-05-29       Impact factor: 3.160

Review 8.  Radiation-induced neuropathies in head and neck cancer: prevention and treatment modalities.

Authors:  Patrick Azzam; Manal Mroueh; Marina Francis; Alaa Abou Daher; Youssef H Zeidan
Journal:  Ecancermedicalscience       Date:  2020-11-03

9.  Efficacy of Platelet-Rich Plasma as an Adjuvant Therapy to Endoscopic Sinus Surgery in Anosmia Patients with Sinonasal Polyposis: A Randomized Controlled Clinical Trial.

Authors:  Ali Goljanian Tabrizi; Mahboobe Asadi; Mehdi Mohammadi; Amirhosein Abedi Yekta; Mohammadreza Sohrabi
Journal:  Med J Islam Repub Iran       Date:  2021-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.